GLP-1 Navigator
Coverage Intelligence
Cost guide

Wegovy cost without insurance: 2026 prices & how to pay less

Wegovy's list price is well over $1,000/month — but very few patients actually pay that. Here's what Wegovy really costs without insurance in 2026, and the legitimate programs that can bring it under $500/month.

Key takeaways
  • List price (WAC): ~$1,349/month
  • NovoCare direct-pay: $499/month for all doses
  • Wegovy Savings Offer: as low as $0/month for commercially insured patients
  • No FDA-approved generic available — patents extend to ~2031

The list price vs. what people actually pay

Wegovy's wholesale acquisition cost (WAC) is approximately $1,349 per month in 2026. That number rarely matches what patients pay. Pharmacies layer their own markup, but more importantly, Novo Nordisk offers a direct-to-patient program (NovoCare) that bypasses pharmacy markups entirely — bringing the cash price to $499/month for any dose.

NovoCare ($499/month direct pay)

NovoCare is Novo Nordisk's direct-to-patient pharmacy. Patients with a valid Wegovy prescription can order all approved doses at $499/month, shipped to their home.

Eligibility: U.S. residents with a valid prescription. You must not be using any insurance benefit to pay — NovoCare is a true cash program. It is currently the lowest legitimate price for Wegovy without insurance.

Wegovy Savings Offer (for commercially insured)

If you have commercial insurance that covers Wegovy, the Wegovy Savings Offer can reduce your monthly copay to as low as $0 (with a $225 monthly cap on the program's contribution). It cannot be combined with Medicare, Medicaid, or other government programs.

Patient assistance for low-income patients

Novo Nordisk's Patient Assistance Program (PAP) provides Wegovy at no cost to patients who are uninsured, U.S. residents, and below 400% of the federal poverty level. Applications are reviewed monthly; approval typically takes 2–4 weeks.

Why compounded semaglutide is no longer a budget option

Between 2022 and early 2025, compounding pharmacies legally produced semaglutide at $200–$300/month because the FDA listed semaglutide on its drug shortage list. In 2025 the FDA officially declared the shortage resolved, ending mass compounding. Continuing to sell compounded semaglutide is now restricted to narrow clinical exceptions — making it an unreliable cost-saving option.

What to do before paying cash

Before paying $499 out of pocket, confirm whether your plan covers Wegovy under either the obesity indication (BMI ≥ 30, or ≥ 27 with a comorbidity) or the cardiovascular indication (established CVD with overweight/obesity). The cardiovascular indication is increasingly covered by plans that exclude weight-loss drugs — and your prescriber may be able to file under it if you qualify.

Frequently asked questions

See if your plan will cover Wegovy

Get an approval-likelihood score for your insurance plan before paying out of pocket — many patients qualify under the cardiovascular indication.

Educational guidance only — not medical or legal advice.